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Abstract
The vastness of clinical data and the progressing specialization of medical knowledge may lead to misinterpretation
of medication efficacy. To show a realistic perspective on drug efficacy we present meta-analyses on some of the
most commonly used pharmacological interventions. For each pharmacological intervention we present statistical
indexes (absolute risk or response difference, percentage response ratio, mean difference, standardized mean
difference) that are often used to represent efficacy. We found that some of the medications have relatively low
effect sizes with only 11 out of 17 of them showing a minimal clinically important difference. Efficacy was often
established based on surrogate outcomes and not the more relevant patient-oriented outcomes. As the
interpretation of the efficacy of medication is complex, more training for physicians might be needed to get a
more realistic view of drug efficacy. That could help prevent harmful overtreatment and reinforce an evidence-
based, but personalized medicine.
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Background
Medicine is becoming so highly specialized and the clin-
ical literature is growing so fast, that few doctors let
alone the lay public have a working knowledge of the
detailed evidence on drugs outside their specialty [1].
This is despite the fact that clinicians must often evalu-
ate comparative risks and benefits of treatments for pa-
tients with multiple maladies. Studies show that decision
making can be distorted by various cognitive biases such
as a physician’s tendency to remember dramatically suc-
cessful cases and forget ones that failed or to misinter-
pret the statistical indices used in clinical trials and
meta-analyses [2]. This may lead the physician to over-
estimate the efficacy of treatments, which in turn may
be one of the causes of harmful overtreatment [3].
Common pharmacological treatments
We would like to present a realistic perspective on the
general efficacy of common pharmacological treatments.
Following the general methods of a previous overview of
reviews [4], we identified systematic reviews of random-
ized controlled trials with meta-analysis comparing
drugs used in specific therapy types with placebo. We
included 20 most common therapy types as measured
by the number of on-therapy patients in the US, accord-
ing to the IMS Institute for Healthcare Informatics [5].
For each therapy type listed there we identified primary
pharmacological treatments and their primary indica-
tions (as suggested by the IMS review and verified by
national and international treatment guidelines). Then
using PubMed we searched (last search: 5 August 2014,
see Additional file 1) for the broadest and most recent
meta-analysis on that treatment. If possible, we included
meta-analyses on monotherapy rather than combination
therapy, on all patients rather than a sub-group of
patients (for example, we preferred reviews on all age
groups, over ones restricted to adults or children) and
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on broad drug classes rather than narrow ones or single
drugs (for example, we preferred a meta-analysis on all
antihypertensive drugs, over ones on ACE inhibitors or
enalapril). If a meta-analysis on the whole therapy type
(for example, any narcotic) was not available, we in-
cluded a frequently used example (for example, oxy-
codone + paracetamol, which is the most frequently used
painkiller according to the IMS report for which we
found a meta-analysis fulfilling our inclusion criteria).
For a more detailed description of our methods, please
refer to the protocol (see Additional file 2).
Measures of medication efficacy
Figure 1 lists examples of medications used primarily in
the 20 most common therapy types together with a
number of statistical indices. Here we explain how these
measures are calculated and give some examples:
1) Absolute risk or response difference (ARD) is the
risk or percentage of responders in group B
subtracted from the risk or percentage of responders
in group A. For example, mortality was 2 % for drug
treatment and 4 % for placebo, which gives an
ARD = |-2 %|. For responder rates, if 45 % of
patients responded in the drug group and 30 % in the
placebo group, the ARD is 15 %.
2) Percentage response ratio (PRR) is the percentage of
responders in group A divided by the percentage
responders in group B. For example, if 45 % of
participants responded to drug treatment in group A
and 30 % to placebo in group B, the PRR is 50 %,
because 0.45/0.3 = 1.5. This means that there were
50 % more responders in group A compared to
group B.
3) Mean difference (MD) is the mean from group B
subtracted from the mean in group A. For example,
if the mean total sleep time at the end of treatment
in the drug group was 5 hours and 10 minutes and
in the placebo group 4 hours and 55 minutes, the
MD is 15 minutes.
4) Standardized mean difference (SMD) is the mean
from group B subtracted from the mean in group A
and divided by the pooled standard deviation (SD).
For example, if the average weight of participants at
the end of treatment was 79 kg in the drug group
and 83 kg in the placebo group and the pooled SD
was 8 kg, the SMD is 0.5.
Effect sizes at Fig. 1 are expressed graphically as SMDs
and are ranked as “small” (0.2), “medium” (around 0.5)
or “large” (above 0.8) [6]. We also present the percentage
of responders in the drug and placebo group and, if
appropriate, the number of trials (N) and patients (n) for
each meta-analysis, as well as the AMSTAR score, which
is a measure of methodological quality of systematic
reviews [7].
The efficacy of common medications
Differences larger than one standard deviation (that is,
SMD >1) between the drug and placebo groups are
uncommon, examples being proton pump inhibitors for
reflux esophagitis [8] or oxycodone plus paracetamol for
postoperative pain [9]. For many other medications the
effect sizes were much smaller. For example, antihyper-
tensive drugs reduced systolic and diastolic blood pres-
sure by only 10 mmHg and 5 mmHg, respectively [10],
the ARD between aspirin and placebo for primary pre-
vention of cardiovascular events was only 0.07 % per
year [11], and the ARD for antidepressants and placebo
for major depressive disorder was 17 % [12].
For an outcome affecting quality of life, ½ of a
standard deviation is considered to be a minimal clinic-
ally important difference [13]. Out of 17 common
pharmacological treatments examined, only 11 met this
threshold. In four of them efficacy was represented by
surrogate outcomes, such as diastolic blood pressure or
fasting plasma glucose, and not patient-oriented out-
comes, such as pain, mortality or adverse events. There-
fore, patients might not have experienced substantial
benefits related to their well-being and quality of life
after therapy with some of these drugs. Moreover many
of the included meta-analyses had a low methodological
quality as represented by median AMSTAR score of
7/11 (interquartile range 5 to 9).
Surrogate outcomes versus patient-oriented outcomes
Figure 1 also illustrates that surrogate outcomes often
show dramatic effects, while the effects on patient-
oriented outcomes are much smaller. For example,
statins reduce cholesterol by 30 % on average [14]. How-
ever, high cholesterol alone does not directly produce
pain or disability. For long-term consequences, such as
cardiovascular events and mortality, the effects are
smaller (ARD between statins and placebo of 4 % for
cardiovascular events and 1.2 % for mortality within
5 years [15]). In hypertension, medium effect sizes for
reductions of hypertension [10] lead to comparatively
small reductions of cardiovascular events [16], and met-
formin strongly reduces glucose [17], but there is no evi-
dence of a reduction in mortality [18]. Among the seven
outcomes that can be both objectively measured and are
patient-oriented (marked in red color in Fig. 1) only one
shows a big effect size (remission of reflux esophagitis
by proton pump inhibitors [8]).
Statistical indices can be misleading
In general, relative risk reductions suggest larger differ-
ences than ARDs. For example, statins reduced the
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number of patients with major cardiovascular events
from 18 % to 14 % [15]. The relative risk reduction of
21 % (100 % - (14 %/18 %) = 21 %) is more impressive
than the ARD of 4 % (14 % - 18 % = |-4 %|). Findings
consistently show that a mere reporting of a relative risk
reduction can be misleading, because many clinicians
will interpret it as an absolute difference [19].
Limitations
There are many limitations in an overview of meta-
analyses [4]. For example, the meta-analyses differed in
methods and publication year. We preferred reviews of
drug classes which may obscure superiorities of single
drugs. Many outcomes may accumulate over time if the
studies had longer durations. For example, the evidence
on mortality reduction by statins is based on 5-year
studies, but the effect could get larger if patients took
them for 20 years. Or a patient with depression may
have ten episodes in his life which could be reduced by
medication to five [20]. Finally, whether the increment
of improvement by a drug is important depends on
many factors, such as the seriousness of the disease,
side-effects, cost and, most importantly, the short- and
long-term outcome in question. For mortality, the
“baseline risk” (that is, mortality in the no-treatment
group) is often low, leading to a relatively low maximally
possible absolute risk reduction. For example, within
5 years without treatment only 9.7/100 participants with
hypercholesterolemia died [15], limiting the maximally
possible absolute mortality reduction to 9.7 %. Neverthe-
less, since mortality is such an important outcome, even a
small reduction can be clinically meaningful. In other
words, a large effect size for a transitory rash is less
important than a small reduction of death. For all these
reasons, this article is only a perspective and not a full
review of the evidence for every possible aspect.
Conclusions
We feel that we need to be more realistic about drug
efficacy. Doctors may believe that all patients respond to
drugs and none to placebo, but neither statement is true
because there is no ideal drug and many disorders remit
spontaneously due to their natural course. Our prefer-
ence for black or white over shades of grey is convenient
but it can offer only a “false clarity” [21]. The psycholo-
gist Daniel Kahneman received the Nobel Prize in eco-
nomics for research on cognitive bias and decision
making, seen in the context of an initial perception of an
idea, which takes place in less than a second versus the
more logical thinking through of ideas, which often
takes hours or days [22]. The initial rapid intuitions can
be biased by many factors such as recency, frequency
and vividness of prior personal experiences, but does not
take into account statistics very well. Pharmaceutical
company advertising takes full advantage of this. We feel
these quantitative benchmarks will help clinicians learn
how to interpret the latest drug findings and reflect on
their limitations. We do not strive to therapeutic nihil-
ism, but rather believe that drug data is complex and
requires thoughtful consideration regarding which medi-
cations and therapies are best suited for certain situa-
tions and patients.
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Fig. 1 Summary of effect sizes for common pharmacological treatments. The figure presents primary pharmacological intervention for a given
therapy type, the primary outcome, descriptive statistics and efficacy measures. Effect sizes are expressed as standardized mean difference with
corresponding confidence intervals on the right side and the AMSTAR score below. The graph in the middle shows a ranking of effect sizes
according to Cohen: small effect size is no bigger than 0.2; medium effect size is around 0.5; and large effect sizes are bigger than 0.8. Marked
with red color are outcomes that can be objectively measured and are patient-oriented [8–12, 15–18, 23–32]. The following drugs listed by the
IMS Institute report were not included in the figure: thyroid preparations (no meta-analysis was found); anti-epileptics (no meta-analysis
on monotherapy was found because current antiepileptic trials are add-on); hormonal contraceptives for birth control (no “disease” as an
indication); and alpha-adrenergic antagonists for benign prostate hyperplasia (no SMD was provided or calculable). All values are statistically significant
(except mortality for metformin). All additional confidence intervals can be obtained from the authors upon request. AMSTAR, a measurement scale for
the assessment of the methodological quality of systematic reviews; ARD, absolute risk or response difference; CI, confidence interval; D, percentage of
patients with the outcome in the drug group; MD, mean difference in original units; n, number of participants; N, number of trials; PL, percentage of
patients with the outcome in the placebo group; PRR, percentage response ratio; SMD, standardized mean difference
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